Show simple item record

dc.rights.licenceAttribution-NonCommercial 4.0 International*
dc.contributor.authorDomínguez Perilla, Aura María
dc.contributor.authorVásquez, Gloria María
dc.contributor.authorRojas-Reyes, María Ximena
dc.date.accessioned2021-05-05T12:23:12Z
dc.date.available2021-05-05T12:23:12Z
dc.date.created2019-05-20
dc.identifierhttps://login.ezproxy.javeriana.edu.co/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=edselp&AN=S0121812318300963&lang=es&site=eds-livespa
dc.identifier.issn0121-8123spa
dc.identifier.urihttp://hdl.handle.net/10554/53787
dc.description.abstractObjetivo: Determinar si la seropositividad en pacientes con artritis reumatoide tratados con adalimumab (ADL), se asocia a la presencia de anticuerpos anti-adalimumab (anti-ADL). Materiales y métodos: Es un estudio observacional descriptivo que incluyó pacientes con diagnóstico de artritis reumatoide según criterios ACR 1987, que estaban en tratamiento con ADL como primer biológico, por al menos 6 meses. Todos los pacientes se evaluaron para factor reumatoide, anticuerpos anticitrulina, velocidad de sedimentación globular, proteína C reactiva, índices clinimétricos y nivel de anticuerpos anti-ADL. Resultados: Se evaluaron 80 pacientes con edad promedio de 56 anos, ˜ el 86% fueron mujeres, la duración promedio de la enfermedad fue de 15 anos ˜ y el tiempo de exposición a ADL de 52 meses (valor mediano). La seropositividad para factor reumatoide tendió a ser mayor en los pacientes que desarrollaron anticuerpos anti-ADL en comparación con los que no (90,5% vs. 66,1%). La magnitud de la asociación entre factor reumatoide y la presencia de anticuerpos anti-ADL tendió a ser fuerte y estadísticamente significativa (OR = 4,87; IC 95%: 1,03-23,03). Los análisis ajustados de regresión multivariable mostraron una asociación fuerte (OR = 9,77; IC 95%: 1,74-54,79) entre la seropositividad y la presencia de anticuerpos anti-ADL, que dado el bajo número de pacientes carece de precisión (IC 95% muy amplios). Conclusiones: Los pacientes seropositivos tienden a presentar más anticuerpos anti-ADL; sin embargo, se requiere tener un mayor tamano˜ muestral para obtener la precisión necesaria y tener mayor certeza en estos hallazgos.spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectArtritis reumatoidespa
dc.subjectTerapia biológicaspa
dc.subjectInmunogenicidadspa
dc.subjectAdalimumabspa
dc.subjectAnticuerpos anti-adalimumabspa
dc.title¿Is seropositivity in patients with rheumatoid arthritis treated with adalimumab a factor to develop anti-adalimumab antibodies?spa
dc.title.alternative¿Es la seropositividad en pacientes con artritis reumatoide tratados con adalimumab un factor para desarrollar anticuerpos anti-adalimumab?spa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.description.quartilescopusQ4spa
dc.identifier.doihttps://doi.org/10.1016/j.rcreu.2018.10.001spa
dc.subject.keywordRheumatoid arthritisspa
dc.subject.keywordBiological therapyspa
dc.subject.keywordImmunogenicityspa
dc.subject.keywordAnti-adalimumab antibodiesspa
dc.description.abstractenglishObjective: To determine whether seropositivity in rheumatoid arthritis patients treated with adalimumab (ADL) is associated with the presence of anti-adalimumab (anti-ADL) antibodies. Materials and methods: A descriptive observational study that included patients diagnosed with rheumatoid arthritis according to ACR 1987 criteria, and who were on treatment with ADL as the first biological, for at least six months. All patients were evaluated for rheumatoid factor, anti-citrulline antibodies, erythrocyte sedimentation rate, C-reactive protein, clinimetric indices, and level of anti-ADL antibodies. Results: A total of 80 patients with a mean age of 56 years were evaluated, of whom 86% were women. The mean duration of the disease was 15 years, and the ADL exposure time was 52 months (median value). The seropositivity for rheumatoid factor tended to be higher in patients who developed anti-ADL antibodies compared to those who did not (90.5% vs. 66.1%). The magnitude of the association between rheumatoid factor and the presence of anti-ADL antibodies was shown to be strong and statistically significant (OR = 4.87, 95% CI; 1.03–23.03). Adjusted multivariate regression analyses showed a strong association (OR = 9.77, 95% CI; 1.74–54.79) between seropositivity and the presence of anti-ADL antibodies, which, given the low number of patients, lacks precision (95% CI very wide). Conclusions: Seropositive patients tend to have more anti-ADL antibodies. However, a larger sample size is required to obtain the necessary precision and greater certainty in these findings.spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.type.localArtículosspa
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.description.orcidhttps://orcid.org/0000-0001-5752-7653spa
dc.relation.citationstartpage24spa
dc.relation.citationendpage30spa
dc.relation.ispartofjournalRevista Colombiana de Reumatologíaspa
dc.description.indexingN/Aspa
dc.relation.citationvolume26spa
dc.relation.citationissue1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International